NCT06110715

Brief Summary

TACS is an emergent method of non-invasive neuromodulation which can engage frequency-specific brain oscillations. It is increasingly recognized that neural oscillations play a system-organizing role in the brain. Evidence suggests that disorganized neural oscillations may also influence functionality of cognitive processes such as working memory. Thus, as TACS can affect neural oscillatory activity in the human brain in a non-invasive manner, it has promise to transform mental health care. The premise of this proposed work is that tACS concurrent with multi-session working memory (WM) focused skills will facilitate durable working memory and stabilized neural oscillations. Depression offers an excellent model to study the effects of tACS. The study seeka to administer 2mA of tACS using theta oscillations to improve working memory concerns associated with depression. The purpose of this study is to investigate the electrophysiological and behavioral effects of transcranial alternating current stimulation (tACS) in humans and to explore specific improvements in working memory and depressive symptoms. This study is placebo-controlled study. Participants will undergo pre- and post-assessments and either theta or sham tACS for 5 days. During each session, the volunteer will perform cognitive tasks while receiving tACS. Assessment sessions will include cognitive tasks, questionnaires, a clinical interview, and EEG.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2023

Shorter than P25 for not_applicable depression

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 5, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 16, 2023

Completed
16 days until next milestone

First Posted

Study publicly available on registry

November 1, 2023

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 16, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 16, 2024

Completed
Last Updated

September 23, 2024

Status Verified

September 1, 2024

Enrollment Period

12 months

First QC Date

October 16, 2023

Last Update Submit

September 19, 2024

Conditions

Outcome Measures

Primary Outcomes (5)

  • working memory skills

    Using a cognitive task that will consist of test responses (correct / incorrect) and reaction time (in ms). The task will include looking at faces expressing different emotions and matching them with previous images.

    Day 5

  • Resting state EEG

    examine theta power and connectivity with the EEG recordings

    Day 6

  • Resting state EEG

    examine theta power and connectivity with the EEG recordings

    Day 35

  • task-based EEG

    examine theta power and connectivity with the EEG recordings

    Day 6

  • task-based EEG

    examine theta power and connectivity with the EEG recordings

    Day 35

Study Arms (2)

control group

SHAM COMPARATOR

participants with depressive disorder

Other: sham tACS stimulation

Active group

EXPERIMENTAL

participants with depressive disorder

Other: theta tACS stimulation

Interventions

The low intensity transcranial electrical stimulation will be administered with a battery-powered, current-controlled, multi-channel stimulator from Neuroelectrics® Starstim 8. This device comes with a neoprene headcap to hold the electrodes in place. TACS will be delivered concurrently with the task. The multichannel, current-driven stimulator (Neuroelectrics StarStim 8) will be used to control independent stimulation electrodes on the scalp of the volunteer. The stimulation intensity will be up to 2 mA.

Active group

A placebo control stimulation will use an identical montage to the stimulation montage. However, polarities of the electrodes will be such that only a minimal amount of current reaches the brain, which is achieved through controlled current shunting between neighboring electrodes. This so-called ActiSham protocol is a verified method to imitate the sensations of actual tACS, with minimal stimulation of the brain .

control group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age between 18 and 60 years old.
  • Stated willingness to participate and comply with all study procedures.
  • Stated availability for the duration of the study.
  • Meet criteria for Major Depressive Disorder.
  • Agreement to adhere to lifestyle considerations throughout study duration.
  • No conflict of interest with the Department of Biomedical Engineering at the University of Minnesota.
  • Confident level of English language.

You may not qualify if:

  • History or evidence of chronic neurological disorder (e.g., history of seizures, epilepsy, unexplained episodes of loss of consciousness, serious brain injury, severe or frequent headaches)
  • Metal or electric implant in the head, neck or chest area.
  • Implanted pacemakers or other electrically, magnetically, ir mechanically activated implant
  • Vascular clips or other electrically sensitive support systems in the brain
  • Serious health conditions (e.g., congestive heart failure pulmonary obstructive chronic disease, active neoplasia)
  • History of head injuries.
  • Pregnancy or breast-feeding.
  • Significant damage of skin at sites of stimulation or other skin concerns, such as dermatitis, psoriasis, or eczema
  • Alcohol or drug addiction.
  • Any legal reason why the candidate cannot participate.
  • Concurrent enrollment in another scientific or clinical study.
  • Estimated IQ is below 70, defined by the WTAR.
  • Active suicidality or other non-controlled neuropsychiatric illness. Active suicidality will be excluded based on a C-SSRS score of 3 or above in the last 6 months. Severe depression is defined as a PHQ-9 score above 20, which will also be excluded.
  • A lifetime suicide attempt.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Depression

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Study Officials

  • Alexander Opitz, PhD

    University of Minnesota

    PRINCIPAL INVESTIGATOR
  • Kelvin Lim, MD

    University of Minnesota

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 16, 2023

First Posted

November 1, 2023

Study Start

September 5, 2023

Primary Completion

August 16, 2024

Study Completion

August 16, 2024

Last Updated

September 23, 2024

Record last verified: 2024-09